Gilead reports Q4 earnings on Feb. 11. Analysts expect $1.70 EPS. The LEO Pharma deal could reduce 2025 EPS by up to $0.17.

Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced ...

Contrary to prior data, this study shows that neither eosinophils nor STAT6-mediated IL-4/IL-13 signaling contribute ...

LEO Pharma and non-profit organisation DEBRA Research have announced a collaboration aimed at accelerating the development of treatments for epidermolysis bullosa (EB). The non-exclusive strategic ...

Gilead Sciences’ inflammation drug prospects have come via deals, and the latest one brings drug candidates for an elusive target that’s in pursuit by a growing number of companies. The ...

Driven inflammatory disorders like asthma, chronic obstructive pulmonary disease, and atopic dermatitis, the cooperation centers on STAT6, a transcription factor associated with IL-4 and IL-13 ...

Major deals, including Johnson & Johnson’s $14.6B Intra-Cellular acquisition, signal renewed dealmaking, supported by nearly ...

Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th ...

The event will be webcast live and may be accessed via a link in the Investors section of the Nurix website. The archived webcast will be available for 30 days after the event. About Nurix ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

LEO Pharma will be gaining the rights to commercialise Junshi Biosciences’ toripalimab in Europe under a new distribution and marketing partnership. The collaboration is aimed at increasing the ...